AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal to target antibody-drug conjugate concludes busy week in cancer partnering for AbbVie.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
CytomX’s Approach To Antibody-Drug Conjugates Earns Deal With Pfizer
The privately held California biotech calls its ADC technology Probody Drug Conjugates and claims it can create antibodies that will activate in a tumor’s micro-environment, while remaining dormant in healthy tissue. Pfizer is paying $25 million divided between upfront cash and preclinical milestones for a licensing deal around CytomX’s Probody Platform technology.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.